RTTR Ritter Pharmaceuticals, Inc.

0.58
-0.02  -3%
Previous Close 0.60
Open 0.62
Price To book 2.56
Market Cap 8.48M
Shares 14,619,000
Volume 600,113
Short Ratio 2.30
Av. Daily Volume 641,573

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data released March 28, 2017. Primary endpoint met. End of Phase 2 meeting with FDA planned
RP-G28
Lactose intolerance

Latest News

  1. Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates
  2. Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3
  3. Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
  4. Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
  5. Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  6. Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
  7. Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
  8. Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome
  9. Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors
  10. Penny Stocks to Watch for January 2016
  11. Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences
  12. Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
  13. Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
  14. Why These Five Stocks Are Trending Today
  15. Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28
  16. Ritter Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
  17. Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance
  18. Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance